{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:33Z","timestamp":1791876933359,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T00:00:00Z","timestamp":1686700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Neurological deterioration, soon after anti-copper treatment initiation, is problematic in the management of Wilson\u2019s disease (WD) and yet reports in the literature are limited. The aim of our study was to systematically assess the data according to early neurological deteriorations in WD, its outcome and risk factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using PRISMA guidelines, a systematic review of available data on early neurological deteriorations was performed by searching the PubMed database and reference lists. Random effects meta-analytic models summarized cases of neurological deterioration by disease phenotype.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Across the 32 included articles, 217 cases of early neurological deterioration occurred in 1512 WD patients (frequency 14.3%), most commonly in patients with neurological WD (21.8%; 167\/763), rarely in hepatic disease (1.3%; 5\/377), and with no cases among asymptomatic individuals. Most neurological deterioration occurred in patients treated with d-penicillamine (70.5%; 153\/217), trientine (14.2%; 31\/217) or zinc salts (6.9%; 15\/217); the data did not allow to determine if that reflects how often treatments were chosen as first line therapy or if the risk of deterioration differed with therapy. Symptoms completely resolved in 24.2% of patients (31\/128), resolved partially in 27.3% (35\/128), did not improve in 39.8% (51\/128), with 11 patients lost to follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Given its occurrence in up to 21.8% of patients with neurological WD in this meta-analysis of small studies, there is a need for further investigations to distinguish the natural time course of WD from treatment-related early deterioration and to develop a standard definition for treatment-induced effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-023-06895-6","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T03:27:42Z","timestamp":1686713262000},"page":"3443-3455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Early neurological deterioration in Wilson\u2019s disease: a systematic literature review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Agnieszka","family":"Antos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cz\u0142onkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Smolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bembenek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Przyby\u0142kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Skowro\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Kurkowska-Jastrz\u0119bska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2670-9651","authenticated-orcid":false,"given":"Tomasz","family":"Litwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,14]]},"reference":[{"key":"6895_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jhep.2011.11.007","volume":"5","author":"European Association for the Study of the Liver","year":"2012","unstructured":"European Association for the Study of the Liver (2012) EASL clinical practice guidelines: Wilson\u2019s disease. J Hepatol 5:671\u2013685","journal-title":"J Hepatol"},{"key":"6895_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1034\/j.1600-0676.2003.00824.x","volume":"23","author":"P Ferenci","year":"2003","unstructured":"Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky ML, Cox D, Berr F (2003) Diagnosis and phenotypic classification of Wilson disease. Liver Int 23:139\u2013142","journal-title":"Liver Int"},{"key":"6895_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12883-018-1039-y","volume":"18","author":"A Czlonkowska","year":"2018","unstructured":"Czlonkowska A, Litwin T, Dziezyc K, Karlinski M, Bring J, Bjartmar C (2018) Characteristic of newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson\u2019s Disease Rating Scale. BMC Neurol 18:34","journal-title":"BMC Neurol"},{"key":"6895_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","volume":"4","author":"A Czlonkowska","year":"2018","unstructured":"Czlonkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, Rybakowski JK, Weiss KH, Schilsky ML (2018) Wilson disease. Nat Rev Dis Primers 4:21","journal-title":"Nat Rev Dis Primers"},{"key":"6895_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/B978-0-444-63625-6.00015-X","volume":"142","author":"A Czlonkowska","year":"2017","unstructured":"Czlonkowska A, Litwin T (2017) Wilson disease \u2013 currently used anticopper therapy. Handb Clin Neurol 142:181\u2013191","journal-title":"Handb Clin Neurol"},{"key":"6895_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1478-3231.2010.02354.x","volume":"31","author":"R Bruha","year":"2011","unstructured":"Bruha R, Marecek Z, Pospisilova L, Nevsimalova S, Vitek L, Martasek P, Nevoral J, Petrtyl J, Urbanek P, Jiraskova A, Ferenci P (2011) Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 31:83\u201391","journal-title":"Liver Int"},{"key":"6895_CR7","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00415-005-0720-4","volume":"252","author":"A Czlonkowska","year":"2005","unstructured":"Czlonkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M (2005) Wilson\u2019s disease \u2013 cause of mortality in 164 patients during 1992\u20132003 observation period. J Neurol 252:698\u2013703","journal-title":"J Neurol"},{"key":"6895_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cgh.2013.09.025","volume":"12","author":"S Beinhardt","year":"2014","unstructured":"Beinhardt S, Leiss W, Stattermayer AF, Graziadei I, Zoller H, Stauber R, Maieron A, Datz C, Steindl-Munda P, Hofer H, Vogel W (2014) Trauner, M.; Ferenci, P. Long-term outcomes of patients with Wilson disease in a large Austrian cohort. Clin Gastroenterol Hepatol 12:683\u2013689","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6895_CR9","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.cgh.2013.11.009","volume":"12","author":"ML Schilsky","year":"2014","unstructured":"Schilsky ML (2014) Long-term outcome for Wilson disease: 85% good. Clin Gastroenterol Hepatol 12:690\u2013691","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6895_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/nyas.12437","volume":"1315","author":"KH Weiss","year":"2014","unstructured":"Weiss KH, Stremmel W (2014) Clinical considerations for an effective medical therapy in Wilson\u2019s disease. Ann N Y Sci 1315:81\u201385","journal-title":"Ann N Y Sci"},{"key":"6895_CR11","first-page":"197","volume":"86","author":"JM Walshe","year":"1993","unstructured":"Walshe JM, Yealland M (1993) Chelation treatment of neurological Wilson\u2019s disease. Q J Med 86:197\u2013204","journal-title":"Q J Med"},{"key":"6895_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jocn.2007.03.001","volume":"15","author":"TJ Kleinig","year":"2008","unstructured":"Kleinig TJ, Harley H, Thompson PD (2008) Neurological deterioration during treatment in Wilson\u2019s disease: question. J Clin Neurosci 15:575","journal-title":"J Clin Neurosci"},{"key":"6895_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jocn.2012.02.041","volume":"20","author":"B Kim","year":"2013","unstructured":"Kim B, Chung SJ, Shin HW (2013) Trientine-induced neurological deterioration in a patient with Wilson\u2019s disease. J Clin Neurosci 20:606\u2013608","journal-title":"J Clin Neurosci"},{"key":"6895_CR14","first-page":"151","volume":"45","author":"D Mishra","year":"2008","unstructured":"Mishra D, Kalra V, Seth R (2008) Failure of prophylactic zinc in Wilson disease. Indian Pediatr 45:151\u2013153","journal-title":"Indian Pediatr"},{"key":"6895_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/archneur.1987.00520170020016","volume":"44","author":"GJ Brewer","year":"1987","unstructured":"Brewer GJ, Terry CA, Aisen AM, Hill GM (1987) Worsening of neurologic syndrome in patients with Wilson\u2019s disease with initial penicillamine therapy. Arch Neurol 44:490\u2013493","journal-title":"Arch Neurol"},{"key":"6895_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1055\/s-2008-1064976","volume":"115","author":"MJ Hilz","year":"1990","unstructured":"Hilz MJ, Druschky KF, Bauer J, Neundorfer B, Schuierer G (1990) Wilson\u2019s disease \u2013 critical deterioration under high-dose parenteral penicillamine therapy. Dtsch Med Wochenschr 115:93\u201397","journal-title":"Dtsch Med Wochenschr"},{"key":"6895_CR17","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/archneur.1990.00530050119022","volume":"47","author":"JD Glass","year":"1990","unstructured":"Glass JD, Reich SG, DeLong M (1990) Wilson\u2019s disease. Development of neurological disease after beginning penicillamine therapy. Arch Neurol 47:595\u2013596","journal-title":"Arch Neurol"},{"key":"6895_CR18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/archneur.1994.00540150106026","volume":"51","author":"GJ Brewer","year":"1994","unstructured":"Brewer GJ, Turkay A, Yuzbasiyan-Gurkan V (1994) Development of neurologic symptoms in a patient with asymptomatic Wilson\u2019s disease treated with penicillamine. Arch Neurol 51:304\u2013305","journal-title":"Arch Neurol"},{"key":"6895_CR19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/archneur.1997.00550210092019","volume":"54","author":"S Porzio","year":"1997","unstructured":"Porzio S, Iorio R, Vajro P, Pensati P, Vegnente A (1997) Penicillamine-related neurologic syndrome in a child affected by Wilson disease with hepatic presentation. Arch Neurol 54:1166\u20131168","journal-title":"Arch Neurol"},{"key":"6895_CR20","first-page":"104","volume":"22","author":"AC Paul","year":"2003","unstructured":"Paul AC, Varkki S, Yohannan NB, Eapen CE, Chandy G, Raghupathy P (2003) Neurologic deterioration in a child with Wilson\u2019s disease on penicillamine therapy. Indian J Gastroenterol 22:104\u2013105","journal-title":"Indian J Gastroenterol"},{"key":"6895_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1001\/archneur.1989.00520400013007","volume":"46","author":"HS Pall","year":"1989","unstructured":"Pall HS, Williams AC, Blake DR (1989) Deterioration of Wilson\u2019s disease following the start of penicillamine therapy. Arch Neurol 46:359\u2013361","journal-title":"Arch Neurol"},{"key":"6895_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2796.1991.tb00395.x","volume":"229","author":"C Veen","year":"1991","unstructured":"Veen C, Van den Hamer CJA, de Leeuw PW (1991) Zinc sulphate therapy for Wilson\u2019s disease after acute deterioration during treatment with low-dose D-penicillamine. J Intern Med 229:549\u2013552","journal-title":"J Intern Med"},{"key":"6895_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1001\/archneur.1995.00540250012003","volume":"52","author":"JM Walshe","year":"1995","unstructured":"Walshe JM, Munro NAR (1995) Zinc-induced deterioration in Wilson\u2019s disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet. Arch Neurol 52:10\u201311","journal-title":"Arch Neurol"},{"key":"6895_CR24","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/1531-8257(199907)14:4<551::AID-MDS1002>3.0.CO;2-S","volume":"14","author":"GJ Brewer","year":"1999","unstructured":"Brewer GJ (1999) Penicillamine should not be used as initial therapy in Wilson\u2019s disease. Mov Disord 14:551\u2013554","journal-title":"Mov Disord"},{"key":"6895_CR25","doi-asserted-by":"publisher","DOI":"10.15761\/GDT.1000110","author":"K Dziezyc","year":"2016","unstructured":"Dziezyc K, Litwin T, Czlonkowska A (2016) Neurological deterioration or symptom progression in Wilson\u2019s disease after starting zinc sulphate treatment \u2013 a case report. Glob Drugs Therapy. https:\/\/doi.org\/10.15761\/GDT.1000110","journal-title":"Glob Drugs Therapy"},{"issue":"Suppl 2","key":"6895_CR26","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.21037\/atm.2019.02.37","volume":"7","author":"A Czlonkowska","year":"2019","unstructured":"Czlonkowska A, Dziezyc-Jaworska K, Klysz B, Redzia-Ogrodnik B, Litwin T (2019) Difficulties in diagnosis and treatment of Wilson disease -a series of five patients. Ann Transl Med 7(Suppl 2):S73","journal-title":"Ann Transl Med"},{"key":"6895_CR27","doi-asserted-by":"crossref","unstructured":"Ziemssen T, Smolinski L, Czlonkowska A, Akgun K, Antos A, Bembenek J, Kurkowska-Jastrzebska I, Przyby\u0142kowski A, Skowro\u0144ska M, R\u0119dzia-Ogrodnik B (2023) Serum neurofilament light chain and initial severity of neurological disease predict the early neuroloigcal deterioration in Wilson\u2019s disease. Acta Neurol Belg 123:917\u2013925","DOI":"10.1007\/s13760-022-02091-z"},{"key":"6895_CR28","doi-asserted-by":"publisher","first-page":"875694","DOI":"10.3389\/fgene.2022.875694","volume":"13","author":"H Hou","year":"2022","unstructured":"Hou H, Chen D, Liu J, Feng L, Zhang J, Liang X, Xu Y, Li X (2022) Clinical and genetic analysis in neurological Wilson\u2019s disease patients with neurological worsening following chelator therapy. Front Genet 13:875694","journal-title":"Front Genet"},{"key":"6895_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S2468-1253(17)30293-5","volume":"2","author":"KH Weiss","year":"2017","unstructured":"Weiss KH, Askari FK, Czlonkowska A, Ferenci P, Bronstein JM, Bega D, Ala A, Nicholl D, Flint S, Olsson L, Plitz T, Bjartmar C, Schilsky ML (2017) Bis-choline tetrathiomolybdate in patients with Wilson\u2019s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2:869\u2013876","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"6895_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12883-020-01827-9","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang J, Xiao L, Yang W (2020) Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson\u2019s disease. BMC Neurol 20:255","journal-title":"BMC Neurol"},{"key":"6895_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12031-019-01423-8","volume":"70","author":"J Kalita","year":"2020","unstructured":"Kalita J, Kumar V, Misra UK, Parashar V, Ranjan A (2020) Adjunctive antioxidant therapy in neurologic Wilson\u2019s disease improves the outcomes. J Mol Neurosci 70:378\u2013385","journal-title":"J Mol Neurosci"},{"key":"6895_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clineuro.2015.07.013","volume":"138","author":"A Ranjan","year":"2015","unstructured":"Ranjan A, Kalita J, Kumar S, Bhoi SK, Misra UK (2015) A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg 138:31\u201336","journal-title":"Clin Neurol Neurosurg"},{"key":"6895_CR33","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1007\/s10072-020-05013-0","volume":"42","author":"B Samanci","year":"2021","unstructured":"Samanci B, Sahin E, Bilgic B, Tufekcioglu Z, Gurvit H, Emre M, Demir K, Hanagasi HA (2021) Neurological features and outcomes of Wilson\u2019s disease: a single-center experience. Neurol Sci 42:3829\u201333834","journal-title":"Neurol Sci"},{"key":"6895_CR34","doi-asserted-by":"publisher","first-page":"e01596","DOI":"10.1002\/brb3.1596","volume":"10","author":"O De Fabregues","year":"2020","unstructured":"De Fabregues O, Vinas J, Palasi A, Quintana M, Cardona I, Auger C, Vargas V (2020) Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson\u2019s disease with neurological symptoms: a case series. Brain Behav 10:e01596","journal-title":"Brain Behav"},{"key":"6895_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jns.2015.06.010","volume":"355","author":"T Litwin","year":"2015","unstructured":"Litwin T, Dzie\u017cyc K, Karli\u0144ski M, Chabik G, Czepiel W, Czlonkowska A (2015) Early neurological worsening in patients with Wilson\u2019s disease. J Neurol Sci 355:162\u2013167","journal-title":"J Neurol Sci"},{"key":"6895_CR36","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cgh.2013.03.012","volume":"11","author":"KH Weiss","year":"2013","unstructured":"Weiss KH, Thurik F, Gotthardt DN, Schafer M, Teufel U, Wiegand F, Merle U, Ferenci-Foerster D, Maieron A, Stauber R, Zoller H, Schmidt HH, Reuner U, Hefter H, Trocello JM, Houwen RHJ, Ferenci P, Stremmel, (2013) W. Efficacy and safety of oral chelators in tertament of patients with Wilson disease. Clin Gastroenterol Hepatol 11:1028\u20131035","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6895_CR37","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3892\/etm.2013.971","volume":"5","author":"H Chang","year":"2013","unstructured":"Chang H, Xu A, Chen Z, Zhang Y, Tian F, Li T (2013) Long-term effects of a combination of D-penicillamine and zinc salts in the treatment of Wilson\u2019s disease in children. Exp Ther Med 5:1129\u20131132","journal-title":"Exp Ther Med"},{"key":"6895_CR38","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/hep.23182","volume":"50","author":"FHH Linn","year":"2009","unstructured":"Linn FHH, Houwen RHJ, van Hattum J, van der Kleij S, van Erpecum KJ (2009) Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology 50:1442\u20131452","journal-title":"Hepatology"},{"key":"6895_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lab.2005.01.007","volume":"145","author":"M Marcellini","year":"2005","unstructured":"Marcellini M, Di Commo V, Callea F, Devito R, Comparcola D, Sartorelli MR, Carelli G, Nobili V (2005) Treatment of Wilson\u2019s disease with zinc from the time of diagnosis in pediatric patients: a single-hospital 10-year follow-up study. J Lab Clin Med 145:139\u2013143","journal-title":"J Lab Clin Med"},{"key":"6895_CR40","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/01.mcg.0000225670.91722.59","volume":"40","author":"V Medici","year":"2006","unstructured":"Medici V, Trevisan CP, D\u2019Inca P, Barollo M, Zancan L, Fagiuoli S, Martines D, Irato P, Sturniolo GC (2006) Diagnosis and management of Wilson\u2019s disease: results of a single center experience. J Clin Gastroenetrol 40:936\u2013941","journal-title":"J Clin Gastroenetrol"},{"key":"6895_CR41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/archneur.63.4.521","volume":"63","author":"GJ Brewer","year":"2006","unstructured":"Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J (2006) Treatment of Wilson disease with ammonium tetrathiomolybdate IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63:521\u2013527","journal-title":"Arch Neurol"},{"key":"6895_CR42","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1053\/j.gastro.2010.12.034","volume":"140","author":"KH Weiss","year":"2011","unstructured":"Weiss KH, Gothardt DN, Klemm D, Merle U, Ferenci-Foerster D, Schaefer M, Ferenci P, Stremmel W (2011) Zinc monotherapy is not effective as chelating agents in treatment of Wilson\u2019s disease. Gastroenterology 140:1189\u20131198","journal-title":"Gastroenterology"},{"key":"6895_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000355276","volume":"71","author":"J Kalita","year":"2014","unstructured":"Kalita J, Kumar V, Chandra S, Kumar B, Misra UK (2014) Worsening of Wilson disease following penicillamine therapy. Eur Neurol 71:126\u2013131","journal-title":"Eur Neurol"},{"key":"6895_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/archneur.60.3.379","volume":"60","author":"GJ Brewer","year":"2003","unstructured":"Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK (2003) Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 60:379\u2013385","journal-title":"Arch Neurol"},{"key":"6895_CR45","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.21037\/atm.2018.12.09","volume":"7","author":"T Litwin","year":"2019","unstructured":"Litwin T, Dzie\u017cyc K, Czlonkowska A (2019) Wilson disease \u2013 treatment perspectives. Ann Transl Med 7:S68","journal-title":"Ann Transl Med"},{"key":"6895_CR46","first-page":"W65","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. Explanation Elaboration Ann Intern Med 151:W65\u2013W94","journal-title":"Explanation Elaboration Ann Intern Med"},{"issue":"2","key":"6895_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/mds.21201","volume":"22","author":"M Sohtaoglu","year":"2007","unstructured":"Sohtaoglu M, Ergin H, Ozekmekci S, Sonsuz A, Arici C (2007) Patient with late-onset Wilson\u2019s disease: deterioration with penicillamine. Mov Disord 22(2):290","journal-title":"Mov Disord"},{"key":"6895_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.clineuro.2014.09.030","volume":"127","author":"B Berger","year":"2014","unstructured":"Berger B, Mader I, Damjanovic K, Niesen WD, Stich O (2014) Epileptic status immediately after initiation of d-penicillamine therapy in a patient with Wilson\u2019s disease. Clin Neurol Neurosurg 127:122\u2013124","journal-title":"Clin Neurol Neurosurg"},{"key":"6895_CR49","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/jmri.25702","volume":"47","author":"P Dusek","year":"2018","unstructured":"Dusek P, Skoloudik D, Maskova J, Huelnhagen T, Bruha R, Zahorakova D, Niendorf T, Ruzicka E, Schneider SA, Wuerfel J (2018) Brain iron accumulation in Wilson\u2019s disease: a longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography. J Magn Reason Imaging 47:282\u2013285","journal-title":"J Magn Reason Imaging"},{"key":"6895_CR50","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/brain\/awaa231","volume":"143","author":"I Roos","year":"2020","unstructured":"Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S (2020) Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain 143:2742\u20132756","journal-title":"Brain"},{"key":"6895_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/BF00319740","volume":"238","author":"W Oder","year":"1991","unstructured":"Oder W, Grimm G, Kolleger H, Ferenci P, Schneider B, Deecke L (1991) Neurological and neuropsychiatric spectrum of Wilson\u2019s disease: a prospective study of 45 cases. J Neurol 238:281\u2013287","journal-title":"J Neurol"},{"key":"6895_CR52","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1177\/1756285616641598","volume":"9","author":"D Chen","year":"2016","unstructured":"Chen D, Zhou X, Hou H, Feng L, Liu JX, Liang Y, Lin X, Zhang J, Wu C, Liang X, Pei Z, Li Z (2016) Clinical efficacy of combined sodium dimercaptopropanesulfonate and zinc treatment in neurological Wilson\u2019s disease with D-penicillamine treatment failure. Ther Adv Neurol Disord 9:310\u2013316","journal-title":"Ther Adv Neurol Disord"},{"key":"6895_CR53","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jocn.2020.09.017","volume":"81","author":"XX Zhou","year":"2020","unstructured":"Zhou XX, Pu XY, Xiao X, Chen DB, Wu C, Li XH, Liang XL (2020) Observation on the changes of clinical symptoms, blood and brain copper deposition in Wilson disease patients treated with dimercaptosuccinic acid for 2 years. J Clin Neurosci 81:448\u2013454","journal-title":"J Clin Neurosci"},{"key":"6895_CR54","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1097\/MPG.0000000000003196","volume":"73","author":"E Couchonnal","year":"2021","unstructured":"Couchonnal E, Lion-Francois L, Guiilaud O, Habes D, Debray D, Lamireau T, Broue P, Fabre A, Vanlemmens C, Sobesky R, Gottrand F, Bridoux-Henno L, Dumortier J, Belmath A, Poujois A, Jacquemin E, Brunet AS, Bost M, Lachaux A (2021) Pediatric Wilson\u2019s disease: phenotypic, genetic characterization and outcome of 182 children in France. J Pediatr Gastroenterol Nutr 73:e80\u2013e86","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"6895_CR55","doi-asserted-by":"publisher","first-page":"e15917","DOI":"10.1097\/MD.0000000000015917","volume":"98","author":"YL Li","year":"2019","unstructured":"Li YL, Zhu XQ, Tao WW, Yang WM, Chen HZ, Wang Y (2019) Acute onset neurogical symptoms in Wilson disease after traumatic, surgical or emotional events a cross-sectional study. Medicine 98:e15917","journal-title":"Medicine"},{"key":"6895_CR56","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40261-022-01117-x","volume":"42","author":"S Kumar","year":"2022","unstructured":"Kumar S, Patra BR, Irtaza M, Rao PK, Giri S, Darak H, Gopan A, Kale A, Shukla A (2022) Adverse events with d-penicillamine therapy in hepatic Wilson\u2019s disease: a single-center retrospective audit. Clinical Drug Investig 42:177\u2013184","journal-title":"Clinical Drug Investig"},{"key":"6895_CR57","doi-asserted-by":"publisher","first-page":"847436","DOI":"10.3389\/fphar.2022.847436","volume":"13","author":"S Tang","year":"2022","unstructured":"Tang S, Bai L, Hu Z, Chen X, Zhao J, Liang C, Zhang W, Duan Z, Zheng S (2022) Comparison of the effectiveness and safety of d-penicillamine and zinc salt treatment for symptomatic Wilson disease: a systematic review and meta-analysis. Front Pharmmacol 13:847436","journal-title":"Front Pharmmacol"},{"key":"6895_CR58","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0022-2143(98)90039-7","volume":"132","author":"GJ Brewer","year":"1998","unstructured":"Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KJ, Fink JF (1998) Treatment of Wilson\u2019s disease with zinc: XV long term follow-up studies. J Lab Clin Med 132:264\u2013278","journal-title":"J Lab Clin Med"},{"key":"6895_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.trsl.2009.05.002","volume":"154","author":"GJ Brewer","year":"2009","unstructured":"Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, Kluin KJ, Lorincz MT (2009) Treatment of Wilson\u2019s disease with tetrathiomolybdate V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 154:70\u201377","journal-title":"Transl Res"},{"key":"6895_CR60","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.trsl.2010.08.007","volume":"156","author":"N Shimizu","year":"2010","unstructured":"Shimizu N, Fujiwara J, Ohnishi S, Sato M, Kodama H, Kohsaka T, Inui A, Fujisawa T, Tamai H, Ida S, Itoh S, Ito M, Horiike N, Harada M, Yoshino M, Aoki T (2010) Effects of long-term zinc treatment in Japanese patients with Wilson disease: efficacy, stability, and copper metabolism. Transl Res 156:350\u2013357","journal-title":"Transl Res"},{"key":"6895_CR61","first-page":"171","volume":"37","author":"X Zhou","year":"2011","unstructured":"Zhou X, Li XH, Huang HW, Liu B, Liang YY, Zhu RL (2011) Improved Young Scale\u2014a scale for the neurological symptoms of Wilson disease. Chin J Nervous Ment Dis 37:171\u2013175","journal-title":"Chin J Nervous Ment Dis"},{"key":"6895_CR62","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/qjmed\/hci095","volume":"98","author":"LK Prashanth","year":"2005","unstructured":"Prashanth LK, Taly AB, Sinha S, Ravishankar S, Arunodaya GR, Vasudev MK, Swamy HK (2005) Prognostic factors in patients presenting with severe neurological forms of Wilson\u2019s disease. QJM 98:557\u2013563","journal-title":"QJM"},{"key":"6895_CR63","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1365-2036.2009.03959.x","volume":"29","author":"M Wiggelinkhuizen","year":"2009","unstructured":"Wiggelinkhuizen M, Tilanus MEC, Bollen CW, Houwen RHJ (2009) Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. Aliment Pharmacol Ther 29:947\u2013958","journal-title":"Aliment Pharmacol Ther"},{"key":"6895_CR64","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1111\/liv.14179","volume":"39","author":"C Appenzeller-Herzog","year":"2019","unstructured":"Appenzeller-Herzog C, Mathes T, Heeres MLS, Weiss KH, Houwen RHJ, Ewald H (2019) Comparative effectiveness of common therapies for Wilson\u2019s disease: a systematic review and meta-analysis of controlled studies. Liver Int 39:2136\u20132152","journal-title":"Liver Int"},{"key":"6895_CR65","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/mds.28018","volume":"35","author":"P Dusek","year":"2020","unstructured":"Dusek P, Smolinski L, Redzia-Ogrodnik B, Golebiowski M, Skowronska M, Poujois A, Laurencin C, Jastrzebska-Kurkowska I, Litwin T, Cz\u0142onkowska A (2020) Semiquantitative scale for assessing brain MRI abnormalities in Wilson disease: a validation study. Mov Disord 35:994\u20131001","journal-title":"Mov Disord"},{"key":"6895_CR66","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3390\/diagnostics13091554","volume":"13","author":"A Antos","year":"2023","unstructured":"Antos A, Cz\u0142onkowska A, Bembenek J, Skowro\u0144ska M, Kurkowska-Jastrz\u0119bska I, Litwin T (2023) Blood based biomarkers of central nervous system invovlement in Wilson\u2019s disease. Diagnostics 13:1554","journal-title":"Diagnostics"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06895-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06895-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T05:02:24Z","timestamp":1694408544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06895-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,14]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6895"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06895-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,14]]},"assertion":[{"value":"19 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript has been approved for publication by all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}